{"id":"cefepime-meropenem-or-piperacillin-tazobactam","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Diarrhea"},{"rate":"3-10","effect":"Nausea"},{"rate":"2-8","effect":"Headache"},{"rate":"2-5","effect":"Phlebitis at injection site"},{"rate":"1-3","effect":"Allergic reactions (rash, urticaria)"},{"rate":"0.5-1","effect":"Seizures (rare, especially with renal impairment)"}]},"_chembl":{"chemblId":"CHEMBL186","moleculeType":"Small molecule","molecularWeight":"480.57"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cefepime is a fourth-generation cephalosporin, Meropenem is a broad-spectrum carbapenem, and Piperacillin/Tazobactam is a beta-lactam/beta-lactamase inhibitor combination. All three work by disrupting peptidoglycan cross-linking in the bacterial cell wall. Piperacillin/Tazobactam includes tazobactam, a beta-lactamase inhibitor that protects piperacillin from enzymatic degradation by resistant bacteria.","oneSentence":"These are beta-lactam antibiotics that inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to cell wall rupture and bacterial death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:17:34.365Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial infections including pneumonia, intra-abdominal infections, urinary tract infections, and sepsis"},{"name":"Hospital-acquired and community-acquired infections caused by susceptible gram-positive and gram-negative organisms"}]},"trialDetails":[{"nctId":"NCT07484633","phase":"PHASE4","title":"A Randomised Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients.","status":"NOT_YET_RECRUITING","sponsor":"Semmelweis University","startDate":"2026-04","conditions":"Infection, Sepsis, NICU","enrollment":110},{"nctId":"NCT04692181","phase":"PHASE1, PHASE2","title":"SYN-004 Safety and Tolerability in Allo-HCT Subjects","status":"ACTIVE_NOT_RECRUITING","sponsor":"Theriva Biologics, Inc.","startDate":"2021-02-15","conditions":"Acute Graft-Versus-Host Reaction Following Bone Marrow Transplant, Prevention of CDI in Adult Patients Being Treated With IV Beta-lactam Antibiotics","enrollment":36},{"nctId":"NCT07318584","phase":"PHASE2","title":"Cefotetan Therapy for Escherichia Coli Infections","status":"NOT_YET_RECRUITING","sponsor":"Oregon Health and Science University","startDate":"2026-03","conditions":"E Coli Infection, ESBL Producing E.Coli","enrollment":84},{"nctId":"NCT01543334","phase":"","title":"Antibiotic Concentrations Among Critically Ill Patients","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2012-03","conditions":"Administration of Antibiotics in Intensive Care Units","enrollment":98},{"nctId":"NCT05977868","phase":"PHASE4","title":"Comparing Oral Versus Parenteral Antimicrobial Therapy","status":"TERMINATED","sponsor":"West Virginia University","startDate":"2023-08-04","conditions":"Endovascular Infection, Bone and Joint Infection, Skin and Soft Tissue Infection","enrollment":94},{"nctId":"NCT03790631","phase":"","title":"The OPTIMAL TDM Study: Determining Optimal Beta-lactam Plasma Concentrations Through Therapeutic Drug Monitoring","status":"COMPLETED","sponsor":"University of Geneva, Switzerland","startDate":"2019-01-14","conditions":"Beta-lactam Antibiotics, Therapeutic Drug Monitoring, Toxicity","enrollment":771},{"nctId":"NCT04983901","phase":"PHASE2","title":"PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-09-14","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm","enrollment":100},{"nctId":"NCT05102162","phase":"PHASE4","title":"BL Infusion Trial:Beta-lactam Continuous Versus Intermittent Infusion and Associated Bacterial Resistance and Therapy Outcomes in Critically Ill Patients With Severe Pneumonia","status":"TERMINATED","sponsor":"University of Florida","startDate":"2021-12-17","conditions":"Pneumonia","enrollment":35},{"nctId":"NCT03485950","phase":"PHASE2","title":"Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-05-16","conditions":"Other Infectious Diseases","enrollment":100},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT04233996","phase":"PHASE4","title":"Efficacy of Extended Infusion of β-lactam Antibiotics for the Treatment of Febrile Neutropenia in Hematologic Patients","status":"UNKNOWN","sponsor":"Hospital Universitari de Bellvitge","startDate":"2019-06-05","conditions":"Febrile Neutropenia","enrollment":150},{"nctId":"NCT01793012","phase":"","title":"Drug Monitoring of Antibiotics in Critical Care Patients","status":"COMPLETED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2013-03","conditions":"ARDS, Sepsis","enrollment":186},{"nctId":"NCT02581280","phase":"","title":"Population Pharmacokinetics of Teicoplanin, Levofloxacin, Piperacillin/Tazobactam, Meropenem, Vancomycin, Remifentanil, Cefepime, Cefpirome, Sufentanil, Midazolam, Clopidogrel, Ticagrelor, Prasugrel During Veno-arterial Extracorporeal Membrane Oxygenation (VA ECMO)","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2014-12","conditions":"Cardiac Dysfunction","enrollment":56},{"nctId":"NCT03409679","phase":"PHASE3","title":"Pivotal Study in VAP Suspected or Confirmed to be Due to Pseudomonas Aeruginosa","status":"TERMINATED","sponsor":"Polyphor Ltd.","startDate":"2018-03-23","conditions":"Pneumonia","enrollment":41},{"nctId":"NCT02168816","phase":"PHASE2","title":"Efficacy of Oral Antibiotic Therapy Compared to Intravenous Antibiotic Therapy for Osteomyelitis","status":"TERMINATED","sponsor":"Loyola University","startDate":"2014-03-19","conditions":"Osteomyelitis","enrollment":30},{"nctId":"NCT03245879","phase":"NA","title":"Antibiotic Stewardship in Small Hospitals","status":"COMPLETED","sponsor":"Intermountain Health Care, Inc.","startDate":"2013-07","conditions":"Inappropriate Prescribing, Antibiotic Stewardship, Anti-Bacterial Agents","enrollment":30000},{"nctId":"NCT02732327","phase":"PHASE2","title":"Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer","status":"TERMINATED","sponsor":"Forest Laboratories","startDate":"2016-05-17","conditions":"Neoplasms, Febrile Neutropenia","enrollment":2},{"nctId":"NCT01667094","phase":"PHASE4","title":"A Study Comparing Continuous Infusion Antibiotics to Standard Treatment for Lung Infections in Cystic Fibrosis","status":"UNKNOWN","sponsor":"The Alfred","startDate":"2012-09","conditions":"Cystic Fibrosis","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7407,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Maxipime, Merrem"],"phase":"marketed","status":"active","brandName":"Cefepime, Meropenem, or Piperacillin/Tazobactam","genericName":"Cefepime, Meropenem, or Piperacillin/Tazobactam","companyName":"University of Florida","companyId":"university-of-florida","modality":"Small molecule","firstApprovalDate":"","aiSummary":"These are beta-lactam antibiotics that inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to cell wall rupture and bacterial death. Used for Bacterial infections including pneumonia, intra-abdominal infections, urinary tract infections, and sepsis, Hospital-acquired and community-acquired infections caused by susceptible gram-positive and gram-negative organisms.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}